Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TalaCom
NCT04693468Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in solid tumor (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events and Incidence of dose limiting toxicities. Started Dec 2020; status: recruiting.
02
Drugs
talazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04693468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693468.